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Abstract
Background: Resistance to thyroid hormone beta (RTHβ) is a rare and usually dominantly inherited syndrome caused
by mutations of the thyroid hormone receptor β gene (THRB). In severe cases, it is rarely challenging to control
manifestations using daily therapeutic replacement of thyroid hormone.
Case presentation: The present case study concerns an 8-year-old Japanese girl with a severe phenotype of RTH
(TSH, fT3, and fT4 were 34.0 mU/L, >25.0 pg/mL and, >8.0 ng/dL, respectively), caused by a novel heterozygous
frameshift mutation in exon 10 of the thyroid hormone receptor beta gene (THRB), c.1347-1357 del actcttccccc :
p.E449DfsX11. RTH was detected at the neonatal screening program. At 4 years of age, the patient continued to
suffer from mental retardation, hyperactivity, insomnia, and reduced resting energy expenditure (REE), despite daily
thyroxine (L-T4) therapy. Every-other-day high-dose liothyronine (L-T3) therapy improved her symptoms and increased
her REE, without thyrotoxicosis.
Conclusion: In a case of severe RTH, every-other-day L-T3 administration enhanced REE and psychomotor development,
without promoting symptoms of thyrotoxicosis. Every-other-day L-T3 administration may be an effective strategy for the
treatment of severe RTH.
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Background
Resistance to thyroid hormone beta (RTHβ, #MIM
188570) is a rare syndrome characterized by reduced
responsiveness of some target tissues to thyroid hormone.
RTHβ is usually inherited as an autosomal dominant trait,
and is primarily caused by a mutation of the thyroid
hormone receptor β gene (THRB) [1]. THRB is located on
chromosome 17 and consists of 10 exons. More than 100
mutations have been reported; with the exception of 1
family, all mutations are located on exons 7–10 [2]. The
mutant receptors are able to interfere with the function of
the wild-type receptor, known as a dominant-negative
effect. As such, heterozygous carriers often suffer from
RTHβ. The symptoms of RTHβ are variable depending on
the type of mutation. Many patients show a mild pheno-
type, and typically, treatment is not required. Heterozy-
gous mutations resulting in truncated THRB cause a
severe phenotype. Specifically, THRB lacking the last
20–28 amino acid residues causes mental retardation,
visual and auditory deficits, and short stature [3]. Pa-
tients with biallelic mutations of THRB also develop a
severe phenotype [4, 5]. Most children with RTHβ ex-
perience attention-deficit hyperactivity disorder
(ADHD) [6]. In children with RTHβ and ADHD, par-
ticularly those who exhibit hyperactivity, liothyronine
(L-T3), in supra-physiological doses, may be beneficial
in reducing hyperactivity and impulsivity [7].
We report a severe case of RTHβ in an 8-year-old girl,
in whom we detected a novel heterozygous deletion
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mutation of THRB, which generates a truncated protein.
The patient experienced mental retardation, hyperactivity,
and insomnia, despite treatment with thyroxine (L-T4)
therapy. Using every-other-day L-T3 therapy in large
doses improved her symptoms without thyrotoxicosis.
Case presentation
The ethics committee of the Shiga University of Medical
Science approved the study. The patient is the first child
of the family, born to non-consanguineous parents with-
out a family history of thyroid disease. Informed consent
was obtained from the patient’s parents.
At 20 days of age, the patient’s serum TSH level in-
creased to 198 μU/mL at neonatal screening. At 26 days
of age, she visited our outpatient clinic exhibiting
failure to thrive, persistent jaundice, and umbilical her-
niation. The patient’s serum TSH, fT3, fT4, total T3,
total T4, and TG values were 34.0 mU/L, >25.0 pg/mL,
>8.0 ng/dL, 6.20 ng/mL, >24.9 μg/dL, and >800 ng/mL,
respectively. She had no signs of heat intolerance,
tachycardia, or hyperactivity. Thyroid gland enlarge-
ment and delayed bone maturation were noted. Pituit-
ary size, as assessed with magnetic resonance imaging,
indicated slight anterior lobe hyperplasia. TRH stimula-
tion tests showed an excessive response (peak TSH: 92
μU/ml). The resting energy expenditure (REE), which
was measured using AE300S (Minato Medical Science,
Japan) by indirect calorimetry [REE (kcal/day) = 5.616 x
VO2 (ml/min) + 1.584 x VCO2 (ml/min)] [8], was one-
third of the normal values typical for her age. No anti-
thyroid antibodies were detected. Based on these
results, the patient was diagnosed with RTH. The
patient was treated with L-T4 replacement starting at
2 weeks of age (7.5 μg/kg/day). After initiating replace-
ment, TSH levels reduced to normal and her weight
gain and REE improved (Fig. 1).
At 2 years of age, the patient showed normal growth
(height and weight). However, she developed mental
retardation [developmental quotient (DQ): 70–60
(postural-motor region 52, cognitive-adaptive region
63, language-social region 68) (the Kyoto Scale of
Psychological Development new edition 2001)] and a
learning disability associated with ADHD. At 4 years
of age, the patient’s DQ reduced to 50 and she
showed symptoms of hyperactivity and insomnia. Her
bone age was delayed about 1.5 years behind her
chronological age, and REE decreased to 78 % of 4-
years-girl. To enhance the patient’s psychomotor de-
velopment and REE, we chose to increase the L-T4
dose. However, considering the consistently high fT3,
secondary to L-T4 therapy which could worsen in-
somnia, hyperactivity, and ADHD, the therapy was
changed to single every-other-day large doses of L-T3
(75 μg). After start of L-T3 every-other-day replace-
ment in one year, her DQ increased to 60 (Fig. 1).
The patient’s insomnia and hyperactivity also im-
proved. At the time of publication, the patient is
8 years, 11 months old, with a height of 131.6 cm
(+0.28 SD). Her recent TSH, fT3, fT4, and TG were
2.92 μIU/mL, 18.5 pg/mL, 6.21 ng/dL, and 85.9 ng/
Fig. 1 Clinical course of the patient. REE; resting energy expenditure, DQ; developmental quotient
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mL, respectively. REE was 109.3 % of the predicted
values for an 8-year-old girl (Fig. 1).
Laboratory testing and sequence analysis
TSH was measured using a fluorescent enzyme immuno-
assay method (TOSHO, Tokyo, Japan). fT4 and fT3 were
measured with a fluorescent enzyme immunoassay
(TOSHO, Tokyo, Japan). Thyroglobulin was measured
by an immunoradiometric assay (EIKEN CHEMICAL,
Tokyo, Japan).
Blood samples were obtained from the patient and her
parents. Genomic DNA was isolated from leukocytes by
the standard protocol. THRB exons were amplified by poly-
merase chain reaction using a previously reported protocol
[9]. The sequences of the amplified DNA fragments were
determined directly using a BigDye® Terminators v1.1 Cycle
Sequencing Kit (Applied Biosystems, CA) and an ABI
PRISM 3130xI Genetic Analyzer (Applied Biosystems, CA).
Homology models of wild type and mutant THRB were
predicted using a molecular operating environment (MOE;
Chemical Computing Group Inc., Montreal, Quebec,
Canada). The query amino acid sequence of human THRB
came from GenPret (Accession number P10828). Thyroid
receptor alpha (PDB code 1NAVA) was selected as a tem-
plate structure by alignment of amino acid sequences in the
MOE protein database [10].
Results
Gene analysis
We detected a novel deletion mutation in exon 10 of
THRB (Fig. 2). The 11 bases of nucleotide sequence,
“actcttccccc” at 1347_1357 were deleted. This deletion
leads to a frameshift, producing a stop at codon 459:
c.1347_1357 del actcttccccc (p.E449DfsX11) (Fig. 1).
Moreover, this mutation introduces changes in the
amino acid sequence from 449–461 “ELFPPLFLEVFED”
to 449–459 “DFVLGSVRGLD”, and causes two amino
acids in the T3 binding domain to be shorter, when
compared with wild type THRB. The patient’s parents
did not show any mutations on THRB.
Comparison of the conformation of wild type with
p.E449DfsX11 THRB
We used MOE to predict model 3D structures of wild
type and p.E449DfsX11 THRB. The p.E449DfsX11
THRB has one different α-helix (amino acid number
450–451) at the C-terminal (Fig. 3). The deletion muta-
tion with amino acid replacement causes significant
changes to the tertiary structure of THRB.
Discussion
Usually, patients with RTH are euthyroid and do not
require treatment with thyroid hormone. However, in
severe cases, to prevent goiter development, daily L-T4
Fig. 2 THRB nucleotide sequences amplified from the genomic DNA of the patient. The mutation, a deletion of “actcttccccc” at position 1347_1357 in
THRB cDNA, changed the amino acid sequence from 449–461 “ELFPPLFLEVFED” to 449–459 “DFVLGSVRGLD” and made two amino acids in the T3
binding domain shorter, when compared with wild type THRB
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or L-T3 therapeutic replacement is necessary. It is rarely
challenging to control manifestations by using daily
therapeutic replacement of L-T4 or L-T3. Every-other-
day L-T3 replacement has shown to be effective for
treating uncontrolled large goiters in patients with
severe RTH, without symptoms of thyrotoxicosis or
severely elevated TSH [11, 12]. However, effects on
psychological and mental improvement have not been
reported. Supra-physiological doses of L-T3 can reduce
hyperactivity and impulsivity [7]. However, for patients
with severe RTH, such as the present case, extreme
elevations in T3 level might worsen psychological and
mental development. Daily L-T4 supplementation also
induces consistently high T3 levels, which may worsen
insomnia, hyperactivity, and ADHD. To suppress TSH
levels and prevent consistently high T3 levels, every-
other-day L-T3 replacement might be an effective. For
RTHβ, treatment of β blocker and 3,5,3'-triiodothyr-
oacetic acid (TRIAC) was also considered as well as
L-thyroxine if necessary. Usually REE of patients with
RTHβ increases. However decline of REE in our pa-
tient suggested that she is in state of hypothyroidism
physically. The treatment with L-T3 was chosen. Her
mutated THRB might strongly interfere function of
the wild THRB. Severe reduction of THRB function
might induce low REE.
The novel mutation, c.1347-1357 del actcttccccc, gen-
erates a premature stop codon at 459 with an altered C-
terminal amino acid sequence (p.E449DfsX11) (Fig. 1).
These changes in the 3-dimensional structure of C-
terminal might cause severe RTH (Fig. 2). These changes
might cause severe RTH in patient with the heterozy-
gous mutation (p.E449DfsX11).
Conclusions
For severe RTH, every-other-day L-T3 therapy may be an
effective therapy to improve REE and psychomotor devel-
opment, without inducing symptoms of thyrotoxicosis.
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